相关实验视频

Updated: Jul 16, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

缓解中枢神经系统中的放射性毒性:质子疗法的作用

Sebastian F Winter^1,2,3, Eugene J Vaios⁴, Helen A Shih⁵

¹Department of Neurology and MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. sfwinter@mgh.harvard.edu.

Current treatment options in oncology

|September 20, 2023

概括

与传统辐射相比,质子疗法可以减少成年脑癌患者的认知衰退和脑体积损失等晚期副作用. 需要进一步的试验来确认益处,并解决潜在的风险,如大脑亡.

科学领域:

神经瘤学神经瘤学
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

中枢神经系统 (CNS) 的放射性毒性是治疗脑瘤的一个重大挑战.
质子疗法对中枢神经系统恶性瘤的光子疗法提供了潜在的剂量分配优势.
在成人中枢神经系统癌症患者中,质子疗法的临床益处仍在研究中.

研究的目的:

讨论质子疗法在缓解中枢神经系统晚期放射性毒性的作用.
审查成年中枢神经系统恶性瘤中质子疗法的优缺点的证据.

主要方法:

审查现有证据,包括有限的临床试验和建模研究.
讨论潜在的好处,如神经认知功能和大脑体积的保存.
考虑潜在的风险,包括脑组织死亡和生物有效性的不确定性.

主要成果:

有证据表明,质子疗法可能比传统放射疗法具有优势,包括更好地保留神经认知功能和大脑体积.
建模研究预测,质子疗法的优异剂量符合性可以减少晚期影响,如血管病变,内分泌病变和二次恶性瘤.
使用质子疗法可能导致大脑组织死亡率更高的可能性需要进一步调查.

结论:

质子疗法显示有望减少晚期放射性毒性在成人中枢神经系统恶性瘤.
进一步的研究和临床试验对于解决不确定性和确认长期益处至关重要.
目前正在进行的比较光子和质子疗法的试验对于建立最佳治疗策略至关重要.

关键词:

成年患者的成年患者.复杂性复杂性复杂性神经毒性神经毒性质子质子质子辐射伤害的伤害.放射性有毒性放射性有毒性

更多相关视频

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

Published on: October 18, 2011

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...